文献速递造血干细胞移植与细胞治疗白血病淋巴瘤

急性淋巴细胞白血病单倍体造血干细胞移植联合移植后环磷酰胺后移植物抗宿主病与复发发生率降低无关:欧洲血液与骨髓移植学会急性白血病工作组研究

Graft-versus-host disease is not associated with reduced incidence of relapse following haploidentical stem cell transplantation with post-transplant cyclophosphamide for acute lymphoblastic leukaemia: A study on behalf of the Acute Leukaemia Working Party of European Society for Blood and Marrow Transplantation.
PubMed 文献 · Br J Haematol · 2025-08-14

该研究纳入516例接受单倍体造血干细胞移植(haploSCT)联合移植后环磷酰胺(PTCy)的成人急性淋巴细胞白血病(ALL)患者,评估急性和慢性移植物抗宿主病(GVHD)对移植结局的影响。结果显示,急性GVHD II-IV级、III-IV级、慢性GVHD及广泛型慢性GVHD的累积发生率分别为33.3%、11.7%、35.3%和11.8%,2年复发发生率(RI)、非复发死亡(NRM)和总生存(OS)分别为27.1%、17.3%和64.4%。急性GVHD III-IV级和广泛型慢性GVHD与更高的NRM和更低的OS相关,但急性和慢性GVHD与RI降低均无统计学关联。

要点

  • 在516例接受haploSCT联合PTCy的成人ALL患者中,急性GVHD II-IV级和III-IV级累积发生率分别为33.3%和11.7%。
  • 慢性GVHD和广泛型慢性GVHD累积发生率分别为35.3%和11.8%,2年RI、NRM和OS分别为27.1%、17.3%和64.4%。
  • 急性GVHD III-IV级和广泛型慢性GVHD与更高的NRM和更低的OS相关,但与RI降低无统计学关联。

核心结论

  • 急性GVHD和慢性GVHD与haploSCT联合PTCy治疗ALL后RI降低均无统计学关联;更高等级的GVHD与更高的NRM和更低的OS相关。

研究设计与样本

  • 该研究为欧洲血液与骨髓移植学会急性白血病工作组开展的研究,纳入516例接受单倍体造血干细胞移植(haploSCT)联合移植后环磷酰胺(PTCy)的成人急性淋巴细胞白血病(ALL)患者,评估急性和慢性GVHD对移植结局的影响。

主要发现

  • 急性GVHD II-IV级和III-IV级累积发生率分别为33.3%和11.7%,慢性GVHD和广泛型慢性GVHD累积发生率分别为35.3%和11.8%。
  • 2年RI、NRM和OS分别为27.1%、17.3%和64.4%。
  • 急性GVHD II级、III-IV级、局限型慢性GVHD和广泛型慢性GVHD与RI关联的时间依赖性HR分别为0.92(95%CI 0.58-1.48,p=0.74)、0.57(95%CI 0.27-1.22,p=0.15)、1.06(95%CI 0.62-1.82,p=0.83)和0.95(95%CI 0.42-2.17,p=0.91)。
  • 急性GVHD III-IV级和广泛型慢性GVHD分别与更高的NRM相关(HR 1.95,95%CI 1.09-3.48,p=0.002;HR 3.3,95%CI 1.41-7.73,p=0.006),并与更低的OS相关(HR 1.91,95%CI 1.07-3.39,p=0.03;HR 3.27,95%CI 1.4-7.66,p=0.006)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The graft-versus-leukaemia effect (GVL) is closely associated with graft-versus-host disease (GVHD) after human leucocyte antigen (HLA)-matched allogeneic stem-cell transplantation (SCT) in acute lymphoblastic leukaemia (ALL). However, there are no data on this association following haploidentical SCT (haploSCT) with post-transplant cyclophosphamide (PTCy). We assessed the impact of acute and chronic GVHD on haploSCT outcomes in 516 adult ALL patients. The cumulative incidence of acute GVHD grade II-IV and III-IV, chronic GVHD and extensive chronic GVHD was 33.3%, 11.7%, 35.3% and 11.8% respectively. The 2-year relapse incidence (RI), non-relapse mortality (NRM) and overall survival (OS) were 27.1%, 17.3% and 64.4% respectively. The time-dependent hazard ratios (HRs) of acute GVHD grade II, grade III-IV, limited and extensive chronic GVHD associated with RI were 0.92 (95% confidence interval [CI] 0.58-1.48, p = 0.74), 0.57 (95% CI, 0.27-1.22, p = 0.15), 1.06 (95% CI, 0.62-1.82, p = 0.83) and 0.95 (95% CI, 0.42-2.17, p = 0.91) respectively. Acute GVHD grade III-IV and extensive chronic GVHD were associated with higher NRM (hazard ratio [HR] 1.95 [95% CI, 1.09-3.48, p = 0.002] and 3.3 [95% CI, 1.41-7.73, p = 0.006]) and reduced OS (HR 1.91 [95% CI, 1.07-3.39, p = 0.03] and 3.27 [95% CI, 1.4-7.66, p = 0.006]) respectively. In conclusion, acute and chronic GVHD are not statistically associated with reduced RI after haploSCT with PTCy in ALL. Higher GVHD grades are associated with higher NRM and lower OS.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Shimoni A, Peczynski C, Labopin M, et al. Graft-versus-host disease is not associated with reduced incidence of relapse following haploidentical stem cell transplantation with post-transplant cyclophosphamide for acute lymphoblastic leukaemia: A study on behalf of the Acute Leukaemia Working Party of European Society for Blood and Marrow Transplantation. Br J Haematol. 2025. PMID: 40810334. doi:10.1111/bjh.70101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。